10-Q: Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results, Announces Restructuring

Phathom Pharmaceuticals reports a net loss of $94.3 million for Q1 2025 and announces a restructuring plan to reduce cash burn and focus on commercial execution.

Summary

• Phathom Pharmaceuticals reported a net loss of $94.3 million for the first quarter of 2025, compared to a net loss of $82.9 million for the same period in 2024.
• Product revenue increased significantly to $28.5 million, up from $1.9 million in the first quarter of 2024, driven by sales of VOQUEZNA products.
• The company is implementing a restructuring plan to reduce cash burn, which includes reducing the workforce by approximately 6% (28 employees) and suspending or deferring certain clinical and product development programs.
• One-time costs associated with the restructuring are estimated to be between $7 million and $10 million, primarily related to termination benefits.
• The company had cash and cash equivalents of $212.3 million as of March 31, 2025.
• Management believes that existing cash and cash equivalents, along with anticipated product revenues, will be sufficient to fund operations for at least the next twelve months.
• The company has drawn down $200 million under its loan agreement with Hercules Capital.
• The company has a revenue interest financing agreement under which investors are entitled to receive a 10% royalty on net sales of products containing vonoprazan.
• As of April 18, 2025, over 390,000 prescriptions for VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak have been filled since launch.
• Over 120 million, or over 80%, of total U.S. commercial lives have access to VOQUEZNA tablets.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue is increasing, losses are also growing, and the company is restructuring to cut costs. The future outlook is uncertain, leading to a neutral to slightly negative sentiment.

Positives

• Product revenue increased significantly to $28.5 million in Q1 2025, indicating growing market acceptance of VOQUEZNA products.
• Over 80% of total U.S. commercial lives have access to VOQUEZNA tablets, suggesting strong market penetration.
• The company believes its existing cash and anticipated revenues are sufficient to fund operations for at least the next twelve months.
• Over 390,000 prescriptions for VOQUEZNA products have been filled since launch as of April 18, 2025.

Negatives

• The company experienced a net loss of $94.3 million in Q1 2025, an increase from the $82.9 million loss in Q1 2024.
• The company is implementing a restructuring plan to reduce cash burn, which includes reducing the workforce by approximately 6% (28 employees) and suspending or deferring certain clinical and product development programs.
• One-time costs associated with the restructuring are estimated to be between $7 million and $10 million, primarily related to termination benefits.
• Based on the current revenue projections, the Company does not expect to meet the revenue threshold to draw the Fifth Tranche or Sixth Tranche under the Loan Agreement.

Risks

• The company has incurred significant operating losses and expects to continue to do so for the foreseeable future.
• The company's future capital requirements will depend on many factors, including its ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payers and adequate market share and revenue for any approved products.
• The company relies on third-party manufacturers for the manufacture of vonoprazan drug substance and drug product for clinical development and commercial sale, and we expect to rely on Sandoz for commercial supplies of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK and the amoxicillin and clarithromycin in those products.
• The company has been informed by Sandoz of a potential disruption in the supply of clarithromycin tablets, a component of VOQUEZNA TRIPLE PAK.

Future Outlook

Based on the current operating plan, the company believes that its existing cash and cash equivalents together with anticipated product revenues, are sufficient to fund operations for at least the next twelve months.

Management Comments

• The commercial launch continues to build momentum and early launch data shows strong physician and patient demand.
• The company continues to make progress in securing broad commercial coverage for VOQUEZNA.
• The company continues to evaluate potential commercial partnerships for vonoprazan in Europe and Canada, expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging, and evaluate the in-license or acquisition of additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.

Industry Context

The market for gastrointestinal disease treatments is competitive, with established players and existing standard-of-care therapies. Phathom's VOQUEZNA faces competition from proton pump inhibitors (PPIs) and other acid-reducing agents. The company's success depends on demonstrating the clinical benefits and cost-effectiveness of VOQUEZNA compared to existing treatments.

Comparison to Industry Standards

• Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia.
• Vonoprazan generated peak net sales of approximately $850 million and continues to achieve volume growth during its tenth full year on the market since its approval in 2014.

Management Changes

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Stakeholder Impact

• Shareholders will be impacted by the restructuring plan and potential changes in the company's strategic direction.
• Employees will be impacted by the workforce reduction of approximately 6%.
• Customers may be impacted by changes in the company's product development and commercialization plans.
• Suppliers and creditors may be impacted by the company's efforts to reduce cash burn.

Next Steps

• Continue commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK in the United States.
• Evaluate potential commercial partnerships for vonoprazan in Europe and Canada.
• Expand development of vonoprazan into other indications, dosing regimens and alternative formulations and packaging.
• Evaluate the in-license or acquisition of additional clinical or commercial stage product candidates for the treatment of GI diseases in a capital efficient manner.

Key Dates

Keywords

VOQUEZNA, Phathom Pharmaceuticals, Vonoprazan, Revenue, Net Loss, Restructuring, GERD, H. pylori, Clinical Trials, Debt, FDA